StartBSX • NYSE
add
Boston Scientific Corp
102,71 $
Efter lukketid:(0,00 %)0,00
102,71 $
Lukket: 12. sep., 16.32.01 GMT-4 · USD · NYSE · Ansvarsfraskrivelse
Seneste lukkekurs
104,34 $
Dagsinterval
102,48 $ - 104,43 $
Årsinterval
80,64 $ - 109,50 $
Markedsværdi
152,19 mia. USD
Gns. volumen
6,27 mio.
P/E-værdi
61,15
Udbytteprocent
-
Primær børs
NYSE
I nyhederne
Økonomi
Resultatopgørelse
Indtægt
Nettoindtægt
(USD) | jun. 2025info | År til år-ændring |
---|---|---|
Indtægt | 5,06 mia. | 22,84 % |
Driftsudgifter | 2,47 mia. | 20,81 % |
Nettoindtægt | 797,00 mio. | 145,99 % |
Overskudsgrad | 15,75 | 100,38 % |
Earnings per share | 0,75 | 20,97 % |
EBITDA | 1,28 mia. | 15,23 % |
Effektiv afgiftssats | 15,52 % | — |
Årsbalance
Samlede aktiver
Samlede passiver
(USD) | jun. 2025info | År til år-ændring |
---|---|---|
Kontanter og korttidsinvesteringer | 534,00 mio. | -81,67 % |
Samlede aktiver | 41,56 mia. | 11,99 % |
Samlede passiver | 18,91 mia. | 14,59 % |
Samlet egenkapital | 22,65 mia. | — |
Shares outstanding | 1,48 mia. | — |
Kurs/indre værdi | 6,89 | — |
Afkast af aktiver | 5,77 % | — |
Afkast af kapital | 6,85 % | — |
Pengestrøm
Nettoændring i likviditet
(USD) | jun. 2025info | År til år-ændring |
---|---|---|
Nettoindtægt | 797,00 mio. | 145,99 % |
Pengestrøm fra drift | 1,29 mia. | 58,18 % |
Pengestrøm fra investering | -1,13 mia. | -315,50 % |
Pengestrøm fra finansiering | -340,00 mio. | -1.516,67 % |
Nettoændring i likviditet | -178,00 mio. | -131,45 % |
Fri pengestrøm | 1,16 mia. | 111,56 % |
Om
Boston Scientific Corporation, is an American biotechnology and biomedical engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
The company is known for the development of the Taxus Stent, a drug-eluting stent which is used to open clogged arteries. The company acquired Cameron Health in June 2012 and began to offer a minimally invasive implantable cardioverter-defibrillator called the EMBLEM subcutaneous implantable defibrillator.
Over the last 20 years, Boston Scientific has had some high-profile patent infringement cases. It has made extensive payouts, including $1.725 billion to Johnson & Johnson, $85 million to Nevro and $42 million to TissueGen.
BSC is headquartered in Marlborough, Massachusetts and incorporated in Delaware. Wikipedia
Administrerende direktør
Grundlagt
29. jun. 1979
Hovedkvarter
Website
Ansatte
53.000